Skip to content

EEG Trajectory-Based Mechanisms of Propofol and Ciprofol in Suppressing Emergence Delirium in Children

EEG Trajectory-Based Mechanisms of Propofol and Ciprofol in Suppressing Emergence Delirium in Children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118968
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Anesthesia Emergence Delirium (PAED)

Interventions

Nested propofol reference group:Propofol 1.0 mg/kg (single intravenous bolus)
Control group:An equal volume of 0.9% normal saline relative to the study drug (ciprofol or propofol).
Ciprofol group:A single intravenous bolus injection of ciprofol (HSK3486) at a dose of 0.25 mg/kg at the end of surgery.

Sponsors

Stomatological Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1.Children aged 3–6 years (including boundary values); 2.American Society of Anesthesiologists (ASA) physical status I or II (i.e., healthy or with mild systemic disease but well-compensated); 3.Scheduled for elective outpatient dental surgery under general anesthesia (including but not limited to dental fillings, root canal therapy, stainless steel crown restoration, and simple tooth extractions), with an expected surgical duration of >=30 minutes; 4.The legal guardian of the child is capable of reading and understanding Chinese and voluntarily signs the written informed consent form.

Exclusion criteria

Exclusion criteria: 1.Known history of allergy to propofol, lipid emulsions, ciprofol, or any components in their formulations; 2.Presence of Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), intellectual disability, or other neurodevelopmental or psychiatric histories that may significantly affect behavioral assessment; 3.Recent (within 2 weeks prior to screening) fever, active upper respiratory tract infection, acute asthma attack, or other severe respiratory diseases; 4.Predicted difficult airway based on preoperative anesthesia assessment (Modified Mallampati Class IV or other difficult airway features); 5.Severe hepatic or renal insufficiency (defined as Child-Pugh Class C or eGFR < 30 mL/min/1.73m^2); 6.History or suspected history of malignant hyperthermia, or a family history of malignant hyperthermia.

Design outcomes

Primary

MeasureTime frame
Pediatric Anesthesia Emergence Delirium Scale;

Secondary

MeasureTime frame
Recovery and extubation times.;Electroencephalogram (EEG) data;Vital signs;The FLACC Pain Scale;

Countries

China

Contacts

Public ContactCong Yu

Stomatological Hospital of Chongqing Medical University

16635470@qq.com+86 23 88602305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026